We are live on
!
Find out more
DB
Dmitry Balyasny Balyasny Asset Management
AUM
$80.2B
1-Year Est. Return
51.53%
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+51.53%
3 Year Est. Return
+149.76%
5 Year Est. Return
+199.37%
10 Year Est. Return
+1,172.21%
AUM
$24B
AUM Growth
+$2.89B
(+14%)
Cap. Flow
+$2.75B
Cap. Flow
% of AUM
11.43%
Top 10 Holdings %
Top 10 Hldgs %
10.27%
Holding
2,691
New
770
Increased
420
Reduced
344
Closed
817
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$537M |
| 2 |
Goldman Sachs
GS
|
+$200M |
| 3 |
Intuit
INTU
|
+$149M |
| 4 |
ExxonMobil
XOM
|
+$149M |
| 5 |
Salesforce
CRM
|
+$141M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PFPT
Proofpoint, Inc.
PFPT
|
+$172M |
| 2 |
WORK
Slack Technologies, Inc.
WORK
|
+$169M |
| 3 |
Amazon
AMZN
|
+$158M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$155M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$142M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.54% |
| 2 | Financials | 12.61% |
| 3 | Industrials | 10.64% |
| 4 | Consumer Discretionary | 9.75% |
| 5 | Healthcare | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LSXMA
401
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
| $15.5M | 0.06% |
447,516
-393,406
| -47% | -$13.7M |
|
402
International Flavors & Fragrances
IFF
$21.5B
| $15.5M | 0.06% |
+115,668
| New | +$17M |
|
403
CALL
Lumentum
LITE
$77.7B
| $15.5M | 0.06% |
+185,000
| New | +$15.5M |
|
404
Philip Morris
PM
$293B
| $15.4M | 0.06% |
162,873
-70,295
| -30% | -$7.07M |
|
405
Helen of Troy
HELE
$677M
| $15.4M | 0.06% |
68,713
+45,033
| +190% | +$10.3M |
|
406
PUT
Match Group
MTCH
$9.38B
| $15.4M | 0.06% |
+98,100
| New | +$14.9M |
|
407
Columbia Sportswear
COLM
$3.09B
| $15.3M | 0.06% |
159,546
+150,249
| +1,616% | +$15.2M |
|
408
Neurocrine Biosciences
NBIX
$15.5B
| $15.3M | 0.06% |
+159,324
| New | +$15M |
|
|
ONEM
409
DELISTED
1Life Healthcare
ONEM
| $15.3M | 0.06% |
+753,236
| New | +$19.4M |
|
410
Cognex
CGNX
$10.2B
| $15.2M | 0.06% |
189,694
-211,545
| -53% | -$18.2M |
|
411
Globus Medical
GMED
$11.7B
| $15.2M | 0.06% |
198,504
+31,751
| +19% | +$2.55M |
|
412
CALL
iShares MSCI Emerging Markets ETF
EEM
$31.2B
| $15.1M | 0.06% |
300,000
+289,184
| +2,674% | +$15.1M |
|
413
NCR Voyix
VYX
$1.09B
| $15M | 0.06% |
631,524
+380,600
| +152% | +$9.9M |
|
414
Tenet Healthcare
THC
$22.6B
| $15M | 0.06% |
225,651
+165,028
| +272% | +$11.7M |
|
|
MTAL
415
DELISTED
Metals Acquisition
MTAL
| $15M | 0.06% |
+1,498,817
| New | +$14.7M |
|
416
Mastercard
MA
$509B
| $15M | 0.06% |
43,045
-241,108
| -85% | -$87.7M |
|
417
CALL
Iovance Biotherapeutics
IOVA
$3.76B
| $14.9M | 0.06% |
605,000
+540,000
| +831% | +$12.7M |
|
|
TMHC
418
DELISTED
Taylor Morrison
TMHC
| $14.9M | 0.06% |
578,571
+153,063
| +36% | +$4.05M |
|
|
RIDE
419
CALL
DELISTED
Lordstown Motors Corp. Class A Common Stock
RIDE
| $14.8M | 0.06% |
+124,000
| New | +$12.9M |
|
|
EQC
420
DELISTED
Equity Commonwealth
EQC
| $14.8M | 0.06% |
567,927
+420,453
| +285% | +$11.1M |
|
421
Cadence Design Systems
CDNS
$87.9B
| $14.7M | 0.06% |
+96,964
| New | +$14.8M |
|
|
CHNG
422
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $14.6M | 0.06% |
698,054
+549,050
| +368% | +$12M |
|
423
Mid-America Apartment Communities
MAA
$15.2B
| $14.5M | 0.06% |
77,470
+40,969
| +112% | +$7.69M |
|
424
CONMED
CNMD
$1.53B
| $14.5M | 0.06% |
+110,571
| New | +$14.5M |
|
425
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$46.3B
| $14.4M | 0.06% |
+100,000
| New | +$14.8M |
|
Similar funds
CBU
Dmitry Balyasny's Q3 2021 Portfolio in Review
As of Q3 2021, Dmitry Balyasny held 2,691 positions worth $24B, up 14% from $21.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Dmitry Balyasny deployed $2.75B of net new capital in Q3 2021, opening 770 new positions and adding to 420 existing holdings. Its largest new stake was Salesforce: 556,949 shares worth $151M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Fortive, an estimated $138M trimmed.
- Dmitry Balyasny's largest Q3 2021 buy was Salesforce: 556,949 shares worth $151M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $537M increase.
- Dmitry Balyasny's biggest Q3 2021 reduction was Fortive, cutting an estimated $138M.
- Dmitry Balyasny fully exited Proofpoint, Inc. in Q3 2021, selling an estimated $172M.
- Dmitry Balyasny's ten largest holdings make up 10% of its $24B portfolio in Q3 2021.
- Dmitry Balyasny opened 770 new positions and closed 817 in Q3 2021.
- Dmitry Balyasny's portfolio value rose 14% quarter-over-quarter to $24B.
Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.